Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab vs Multi-field Radiotherapy for Indolent Cutaneous B-cell Lymphoma
NCT02867553Phase 3Unknown
- Sponsor
- CHU de Reims
- Start
- Oct 2011
- Primary completion
- Jul 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab in cutaneous B-cell lymphoma (CBCL), sponsored by CHU de Reims. Primary endpoint: Disease-free survival at 5 years. Status: unknown.
02
Drugs
rituximab
03
Conditions
cutaneous B-cell lymphoma (CBCL)
Beyond the preview
Go deeper on NCT02867553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02867553.